期刊文献+

活化白细胞黏附分子基因siRNA腺病毒载体构建及其体内外抑制肝癌作用

Antitumor activity of siRNAs targeting ALCAM in HepG2 liver cancer cells in vitro and in vivo
原文传递
导出
摘要 活化白细胞黏附分子(ALCAM)为免疫球蛋白基因超家族成员,存在于人体各组织器官的跨膜糖蛋白中。ALCAM为I型跨膜蛋白,通过异嗜性黏附形式和同嗜性黏附形式介导细胞间黏附脚。有研究结果显示,
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2015年第10期781-783,共3页 Chinese Journal of Hepatology
基金 重庆市自然科学基金项目(2011BB5123)
关键词 腺病手毒科 肝肿瘤 活化白细胞黏附分子 Adenoviridae Liver neoplasms Activatedleukocyte celladhesion molecule
  • 相关文献

参考文献18

  • 1Lunter PC, van Kilsdonk JW, van Beck H, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity[J]. Cancer Res,2005,65( 19): 8801-8808.
  • 2Nelissen JM, Peters IM, de Grooth BG, et al. Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton[J]. Mol Biol Cell, 2000, 11(6): 2057-2068.
  • 3Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy[J]. Med Sci Monit, 2006, 12(8): BR263-273.
  • 4Piao D, Jiang T, Liu G, et al. Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer[J]. Mol Biol Rep, 2012, 39(1): 661-668.
  • 5Luo Q, Kang Q, Song WX, et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing[J].Gene, 2007, 395(1-2): 160-169.
  • 6Datta K, Muders M, Zhang H, et al. Mechanism of lymph node metastasis in prostate cancer[J]. Future Oncol, 2010, 6(5): 823-836.
  • 7Kristiansen G, Pilarsky C C, Stephan C, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions[J]. Prostate, 2003, 54(1): 34-43.
  • 8Tachezy M, Zander H, Gebauer F, et al. Activated leukocyte cell adhesion molecule (CD166)-its prognostic power for colorectal cancer patients[J]. J Surg Res, 2012, 177(1): e15-20.
  • 9Kahlert C, Weber H, Mogler C, et al. Increased expression of ALCAM/CD 166 in pancreatic cancer is an independent prognostic marker for poor survival and early turnout relapse[J]. Br J Cancer, 2009, 101(3): 457-464.
  • 10Tachezy M, Effenberger K, Zander H, et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients[J], lnt J Cancer, 2012, 131(2): 396-405.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部